Back

Dynamic multimodal survival prediction in multiple myeloma integrating gene expression, longitudinal laboratories, and treatment history

JIA, S.; Lysenko, A.; Boroevich, K. A.; Sharma, A.; Tsunoda, T.

2026-04-01 bioinformatics
10.64898/2026.03.30.715136 bioRxiv
Show abstract

Prognostic stratification in multiple myeloma (MM) relies on staging systems that assign patients to fixed categories at diagnosis and discard the temporal information that accumulates during treatment. We developed a dynamic multimodal framework that predicts residual overall survival using observation windows ranging from 1 to 18 months post-diagnosis. The model integrates DeepInsight-transformed gene expression representation, longitudinal laboratory measurement trajectories across 10 analytes, and treatment history for three drug classes through an adaptive fusion mechanism that accounts for missing clinical observations. On the MMRF CoMMpass cohort (n = 752), five-fold cross-validation yielded a concordance index (C-index) of 0.773 {+/-} 0.024 and a time-dependent AUC at a 1-year prediction horizon (tdAUC1yr) of 0.789 {+/-} 0.021, outperforming all evaluated baseline methods including DeepSurv (0.633 {+/-} 0.095) and random survival forests (0.636 {+/-} 0.024) on matched cross-validation splits. Modality ablation identified longitudinal laboratory measurements as the strongest individual contributor (C-index 0.693); the DeepInsight spatial encoding of gene expression yielded higher discrimination than a multilayer perceptron (MLP) baseline operating on the same features (0.624 vs. 0.596). Kaplan-Meier analysis showed significant prognostic group separation at all primary landmarks (log-rank p < 0.001; hazard ratios 3.46-3.93). A distilled student model retaining only the DeepInsight representation and five baseline clinical features achieved C-index 0.672 and tdAUC1yr 0.740 on an independent microarray cohort (GSE24080, n = 507) without retraining. Interpretability analysis identified prognostic associations consistent with established myeloma biology, including ubiquitin-proteasome pathway genes, endoplasmic reticulum stress markers, and Interferon Alpha Response pathway enrichment.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Leukemia
39 papers in training set
Top 0.1%
19.3%
2
Nature Communications
4913 papers in training set
Top 21%
8.7%
3
Bioinformatics
1061 papers in training set
Top 4%
6.6%
4
mAbs
28 papers in training set
Top 0.1%
3.7%
5
Blood Advances
54 papers in training set
Top 0.4%
3.7%
6
Frontiers in Immunology
586 papers in training set
Top 2%
3.2%
7
Scientific Reports
3102 papers in training set
Top 44%
2.7%
8
Cancer Research Communications
46 papers in training set
Top 0.2%
2.4%
50% of probability mass above
9
Communications Biology
886 papers in training set
Top 5%
2.1%
10
npj Precision Oncology
48 papers in training set
Top 0.4%
2.0%
11
eLife
5422 papers in training set
Top 37%
2.0%
12
Clinical Epigenetics
53 papers in training set
Top 0.5%
1.8%
13
Bioinformatics Advances
184 papers in training set
Top 3%
1.8%
14
Cell Reports Medicine
140 papers in training set
Top 3%
1.8%
15
Genome Medicine
154 papers in training set
Top 4%
1.8%
16
JCI Insight
241 papers in training set
Top 4%
1.5%
17
JCO Clinical Cancer Informatics
18 papers in training set
Top 0.5%
1.4%
18
Advanced Science
249 papers in training set
Top 13%
1.4%
19
Nucleic Acids Research
1128 papers in training set
Top 13%
1.3%
20
eBioMedicine
130 papers in training set
Top 2%
1.1%
21
Science Advances
1098 papers in training set
Top 24%
1.1%
22
BMC Bioinformatics
383 papers in training set
Top 6%
0.8%
23
PLOS Computational Biology
1633 papers in training set
Top 23%
0.8%
24
Blood Cancer Journal
11 papers in training set
Top 0.2%
0.8%
25
Cytometry Part A
30 papers in training set
Top 0.3%
0.8%
26
Journal of Thrombosis and Haemostasis
28 papers in training set
Top 0.7%
0.8%
27
Clinical Cancer Research
58 papers in training set
Top 2%
0.8%
28
Computational and Structural Biotechnology Journal
216 papers in training set
Top 9%
0.7%
29
Nature Medicine
117 papers in training set
Top 5%
0.7%
30
Frontiers in Genetics
197 papers in training set
Top 11%
0.7%